Drug Index


Mechanism :

Salmeterol is a selective, long-acting beta2-adrenergic agonist. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including salmeterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3,5 -adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Indication :

  • Persistent Asthma

Contraindications :

Hypersensitivity to any ingredient of the preparation. Should not be started in patients with significantly worsening or acutely deteriorating asthma. Not designed to relieve acute asthma symptoms.

Dosing :

<4 years:
Safety and efficacy not established.
>4 years:
50 mcg (1 oral inhalation) 2 times daily. It should not be used without an asthma controller medication (i.e. inhaled corticosteroid).

Adverse Effect :

Commonly seen adverse effects are pain, nasal congestion, migraine, dizziness, sleep disturbances, tremor, subjective palpitations, headache, tachycardia, hyperglycemia, hypokalemia and paradoxical bronchospasm with aerosol inhaler. Skin reactions, muscle cramps, non-specific chest pain, local irritation and arthralgia have been reported.

Interaction :

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents.
Corticosteroids and Cromoglycate: Inhaled corticosteroids and/or inhaled cromolyn sodium did not alter the safety profile of salmeterol when administered concurrently.
Beta-Adrenergic Receptor Blocking Agents: Beta-blockers not only block the pulmonary effect of beta-agonists, but may also produce severe bronchospasm in patients with asthma or COPD.
Diuretics: The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists.

Hepatic Dose :

Dose reduction may be required as drug has extensive hepatic metabolism and hepatic impairment can cause increased drug accumulation.
01/23/2024 12:26:22 Salmeterol
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0